Tumour- associated autoantibodies as prognostic cancer biomarkers- a review
Document Type
Journal Article
Publication Title
Autoimmunity Reviews
Volume
21
Issue
4
PubMed ID
35032685
Publisher
Elsevier
School
Centre for Precision Health
RAS ID
40664
Abstract
Throughout the process of carcinogenesis, autologous cells are transformed into cancer cells, leading to changes in their protein expression profiles. It has been suggested that mutations, protein misfolding, overexpression and aberrant post-translational modifications, changes in protein abundance or location can render tumour-associated antigens immunogenic. Subsequent changes in the tumour microenvironment may lead to humoral immune responses and therefore the production of tumour-associated autoantibodies. Hence, autoantibodies are suggested to be immunological biomarkers of aberrant cellular mechanisms occurring throughout tumourigenesis. Since autoantibodies represent a stable and amplified signature of the anti-tumour immune response that may be generated prior to the clinical detection of other tumour proteins and prior to the first clinically detectable signs of the cancer or its recurrence, there is great interest in using autoantibodies as diagnostic and prognostic blood-based biomarkers. In this review, we discuss the current evidence supporting the prognostic value of autoantibodies in a highly immunogenic cancer such as melanoma as well as breast, lung, colon, prostate and stomach cancer, the most commonly diagnosed cancers globally in 2020.
DOI
10.1016/j.autrev.2022.103041
Access Rights
subscription content
Comments
Sexauer, D., Gray, E., & Zaenker, P. (2022). Tumour-associated autoantibodies as prognostic cancer biomarkers-a review. Autoimmunity Reviews, 21(4), article 103041.
https://doi.org/10.1016/j.autrev.2022.103041